LNCD(SH:600739) Xin Lang Cai Jing·2025-10-27 05:36Core Viewpoint - Liaoning Chengda's stock price has shown a positive trend with a year-to-date increase of 20.72%, reflecting strong market interest and performance in the pharmaceutical and financial sectors [1][2]. Financial Performance - For the first half of 2025, Liaoning Chengda reported operating revenue of 5.348 billion yuan, a slight decrease of 0.83% year-on-year, while net profit attributable to shareholders increased by 56.18% to 718 million yuan [2]. - Cumulative cash dividends since the company's A-share listing amount to 2.11 billion yuan, with 411 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 5.14% to 66,000, while the average number of tradable shares per person increased by 5.42% to 23,173 shares [2]. - The top ten circulating shareholders include significant institutional investors, with notable increases in holdings from Southern CSI 500 ETF and Hong Kong Central Clearing Limited [3]. Stock Market Activity - On October 27, the stock price rose by 2.13% to 12.47 yuan per share, with a trading volume of 161 million yuan and a turnover rate of 0.85% [1]. - The net inflow of main funds was 7.2843 million yuan, indicating strong buying interest, particularly from large orders [1].